ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1295

Anakinra Is More Effective at Reducing Pain from Acute Crystal Induced Arthritis When Compared to Conventional Therapy: A Retrospective Review at a Tertiary Care Center

Sukhraj Singh1, Anthony Ocon2, Vivek Mehta3, Samah Musa1 and Ruben Peredo2, 1Internal Medicine, Albany Medical Center, Albany, NY, 2Medicine, Albany Medical Center, Albany, NY, 3Division of Rheumatology, Department of Medicine, Albany Medical College, Albany, NY

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Anakinra, crystal-induced arthritis and quality improvement

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: Metabolic and Crystal Arthropathies – Basic and Clinical Science Poster I

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

The management of Acute Crystal-Induced Arthritis (ACIA) relies on NSAIDs, colchicine, and glucocorticoids as conventional therapy. In presence of comorbidities (e.g. renal insufficiency, diabetes mellitus, etc.), conventional treatment may be challenging and may lead to poor hospital outcomes. The IL-1 receptor inhibitor anakinra has effectively treated diseases in which the inflammasome plays a main pathogenic role, including ACIA. We studied inpatients with ACIA receiving anakinra at Albany Medical Center compared to conventional therapy to determine differences in pain scores and length of stay.

Methods:

Single center retrospective chart review of ACIA inpatients between January of 2016 and May 2018 was performed. Data collection included demographics, medications, comorbidities, and Visual Analog Pain Scale (VAS-pain). Response to treatment was defined as a decrease in VAS-pain by more than 2 points on a 0-10 scale at 24, 48, and 72 hours. A 1:2 case-control matched pairing (based on demographics, number of joints affected) were selected as controls from the conventional group. A total of 204 patients meeting ACR/EULAR criteria for ACIA were reviewed. Sixteen patients receiving anakinra for ACIA met selection criteria. Thirty-two patients with conventional treatment were matched with the anakinra group. Repeated measures ANOVA was used to compare each group at each time-point of pain assessment. Tukey-Kramer multiple comparisons test was used for post-hoc comparisons.

Results:

All the patients receiving anakinra had a good response, with statistically significant improvement in pain scores compared to the conventional group (p <0.001). Within the anakinra group, pain was significantly improved at 24 hours (p<0.05) and at 48 hours (p<0.001) compared to baseline. The conventional therapy group had significant improvement at 48 hours compared to baseline (p<0.05) but was not significantly improved at 24 hours (p >0.05). Between groups, pain was not different at baseline or at 24 hours (p >0.05) but was at 48 hours (p<0.001). The average length of stay of patients on anakinra was nearly 2 days shorter in comparison to the conventional group. On average, 3.1 doses (95% CI 2.3 – 3.9) of Anakinra 100mg subcutaneously were required for pain relief. There were no significant adverse events noted.

Conclusion:

Anakinra is an effective treatment for ACIA with faster resolution of symptoms compared to conventional therapy prompting a shortened length of stay. Anakinra may be a safe alternative for patients with contraindications to conventional treatment or who may be at high risk for complications from conventional treatment. Further evaluation of these findings in a prospective study may provide more information regarding a role of anakinra in management of ACIA.

Table 1. Patient Characteristics and Outcomes by Conventional Group versus Anakinra Group.

Variable

Conventional Group(n=32)

Anakinra Group (n =16)

PATIENT CHARACTERISTICS

Age, Mean [95% CI]

63.9 [60.1 – 67.6]

69.0 [62.3 – 75.7]

Sex, No. [%]

Male

18 [56%]

10 [63%]

Female

14 [43%]

6 [37%]

Race, No. [%]

Caucasian

16 [50%]

12 [75%]

African American

11 [34%]

2 [13%]

Hispanic

3 [6%]

1 [6%]

Unknown

None

1 [6%]

Crystal Type, No. [%]

Uric Acid

13 [77%]

9 [56%]

CPPD

3 [18%

1 [6%]

Uric Acid + CPPD

1 [6%]

None

Flare Duration, Days [95% CI]

4.4 [2.9-5.9]

3.3 [2.2 – 4.5]

Diabetes Mellitus, No. [%]

14 [44%]

7 [43%]

CKD Stage 2 or Greater, No. [%]

10 [31%]

9 [56%]

Uric Acid, Mean [SD]

7.2 [2.7]

6.2 [2.2]

Median No. of Joints [Min – Max]

2 [1 – 6]

2 [1 – 5]

Mean ESR [95% CI]

67.1 [55.8 – 78.4]

54.1 [36.2 – 71.9]

Mean CRP [95% CI]

101.1 [71.3 – 131]

146.6 [114 – 179.2]

Renal Function [95% CI]

Blood Urea Nitrogen mg/dL

28.3 [22.7 – 33.9]

25.4 [19.1 – 31.8]

Serum Creatinine mg/dL

1.57 [1.22 – 1.92]

1.81 [0.97 – 2.65]

Glomerular Filtration Rate mL/min/1.73m2

45.3 [40.0 – 50.6]

45.9 [37.0 – 54.8]

OUTCOMES

Mean VAS Pain Score [95% CI]

Before Treatment

7.8 [7.1 – 8.4]

7.9 [6.9 – 8.9]

24 hours after treatmenta

7.3 [6.6 – 8.1]

6.3 [5.3 – 7.4]

48 hours after treatmentb,c

6.7 [5.7 – 7.8]

4.0 [2.5 – 5.5]

72 hours after treatment

6.7 [5.7 – 7.6]

3.1 [1.3 – 4.9]

Mean Length of Stay, Days [95% CI]

7.7 [5.6 – 9.8]

5.5 [4.2 – 6.9]

Median doses of Anakinra [Min – Max] ͩ

None

3 [1 – 9]

Mean doses of Anakinra [95% CI]

None

3.1 [2.3 – 3.9]

Abbreviations: CI, Confidence Interval; SD, Standard Deviation; Min, Minimum; Max, Maximum; ESR, Erythrocyte Sedimentation Rate; CRP, C-Reactive Protein; No, Number; CKD, Chronic Kidney Disease; VAS, Visual Analog Scale; CPPD, Calcium Pyrophosphate Disease

a, Anakinra group has significantly lower pain scores than the conventional group at 24 hours (p<0.05) and at 48 hours (p<0.001)

b, Conventional group had significantly improved at 48 hours compared to baseline (p<0.05) but was not significantly improved at 24 hours (p>0.05)

c, At 48 hours, pain was significantly less in the anakinra group compared to conventional group (p<0.001)

d, Only patients in the anakinra group received it at 100 mg subcutaneously daily.


Disclosure: S. Singh, None; A. Ocon, None; V. Mehta, None; S. Musa, None; R. Peredo, None.

To cite this abstract in AMA style:

Singh S, Ocon A, Mehta V, Musa S, Peredo R. Anakinra Is More Effective at Reducing Pain from Acute Crystal Induced Arthritis When Compared to Conventional Therapy: A Retrospective Review at a Tertiary Care Center [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/anakinra-is-more-effective-at-reducing-pain-from-acute-crystal-induced-arthritis-when-compared-to-conventional-therapy-a-retrospective-review-at-a-tertiary-care-center/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/anakinra-is-more-effective-at-reducing-pain-from-acute-crystal-induced-arthritis-when-compared-to-conventional-therapy-a-retrospective-review-at-a-tertiary-care-center/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology